The Washington Post
Aug 7, 2021 - 7 min
Behind the race for its distribution: on-campus clashes of ego and hastily made threats and promises. AstraZeneca eventually secured a deal to distribute Oxford's yet-to-be-approved vaccine. Why the British pharmaceutical? It could guarantee the university $100 million a year, bridging "Oxford’s history of nonprofit medical innovation and the pharmaceutical industry’s shareholder-driven motivations." In The Wall Street Journal, Jenny Strasburg and Stu Woo report on the remarkable events that transpired.